quinoxalines has been researched along with sodium oxybate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beghè, F; Berton, F; Brancucci, A; Cammalleri, M; Demuro, A; Francesconi, W; Gessa, GL | 1 |
| Cao, F; Cortez, MA; Dong, S; Jia, Z; Joshi, K; Shen, L; Snead, OC | 1 |
2 other study(ies) available for quinoxalines and sodium oxybate
| Article | Year |
|---|---|
Gamma-Hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slices.
Topics: 2-Amino-5-phosphonovalerate; Adjuvants, Anesthesia; Animals; Benzocycloheptenes; Bicuculline; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Antagonists; Hippocampus; In Vitro Techniques; Male; Membrane Potentials; Neurons; Organophosphorus Compounds; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sodium Oxybate | 1999 |
Kcnj6(GIRK2) trisomy is not sufficient for conferring the susceptibility to infantile spasms seen in the Ts65Dn mouse model of down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Down Syndrome; Electroencephalography; Embryo, Mammalian; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Genotype; Hippocampus; Humans; In Vitro Techniques; Infant; Membrane Potentials; Mice; Mice, Inbred C57BL; Patch-Clamp Techniques; Peptide Hydrolases; Quinoxalines; Sodium Oxybate; Spasms, Infantile; Trisomy | 2018 |